VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 200 filers reported holding VAXCYTE INC in Q4 2022. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,289 | -74.5% | 1,163 | -75.1% | 0.00% | -75.0% |
| Q2 2023 | $232,870 | +247634.0% | 4,663 | +86.7% | 0.01% | +166.7% |
| Q1 2023 | $94 | +168.6% | 2,497 | +236.5% | 0.00% | +200.0% |
| Q4 2022 | $35 | -100.0% | 742 | -90.7% | 0.00% | -66.7% |
| Q3 2022 | $191,000 | +4.4% | 7,942 | -5.4% | 0.00% | -25.0% |
| Q2 2022 | $183,000 | +695.7% | 8,395 | +757.5% | 0.00% | – |
| Q1 2022 | $23,000 | -39.5% | 979 | -39.8% | 0.00% | -100.0% |
| Q4 2021 | $38,000 | -5.0% | 1,627 | +3.6% | 0.00% | 0.0% |
| Q3 2021 | $40,000 | -27.3% | 1,570 | -36.2% | 0.00% | 0.0% |
| Q2 2021 | $55,000 | -3.5% | 2,460 | -14.7% | 0.00% | 0.0% |
| Q1 2021 | $57,000 | 0.0% | 2,884 | +34.0% | 0.00% | -50.0% |
| Q4 2020 | $57,000 | -58.1% | 2,152 | -22.1% | 0.00% | 0.0% |
| Q3 2020 | $136,000 | – | 2,761 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |